Prescribing overview
Human oral tablets and external creams have different risks and routes. Neither reviewed human presentation establishes veterinary dosing.
Key prescribing checks
- The human oral label contraindicates use in chronic or active liver disease and calls for liver assessment. Animal-specific eligibility and monitoring require veterinary judgment.
- Review concomitant medication for enzyme-mediated interactions, including drugs affected by CYP2D6 inhibition. This short summary does not replace a full interaction screen.
- Monitor gastrointestinal intolerance, appetite change and suspected hepatic or skin reactions during clinician-directed treatment.
- Confirm the route and prevent ingestion of topical preparations by treated animals or housemates.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Veterinary patients: not established by reviewed label
Extra-label veterinary use; reviewed tablet is human-labeledVeterinarian-selected fungal disease
Human tablet approval concerns dermatophyte nail infections, not a universal animal fungal protocol.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Inhibits fungal squalene epoxidase, impairing ergosterol synthesis; this differs from azole enzyme inhibition.
Absorption, distribution, metabolism and elimination
Reviewed tablet PK is human information; species-specific veterinary absorption, half-life and tissue exposure are not verified here.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Lamisil
Human oral tablets; historical brand identity supported by current generic labeling
Contraindications · when not to use
- Oral tablets: prior allergic reaction to oral terbinafine; chronic or active liver disease.
Precautions & monitoring
- Oral tablets require liver evaluation; serious hepatic, skin and blood reactions are reported.
Lamisil AT
Human topical cream; oral-tablet restrictions are not a substitute for this label
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- OTC do-not-use restrictions: nails/scalp, mouth/eyes or vaginal yeast infections. External use only; stop for worsening irritation.
Human labeling; this does not establish veterinary approval or animal-specific eligibility.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Human oral labeling describes gastrointestinal effects, serious hepatic injury, severe skin reactions and blood disorders; veterinary incidence is unestablished.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
A veterinary dose is not verified. Do not convert a human tablet regimen or administer topical cream orally.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Lamisil
Human oral tablets; historical brand identity supported by current generic labeling
- Oral terbinafine inhibits CYP2D6; review antidepressants, beta blockers and antiarrhythmics. Rifampin, cimetidine, fluconazole and other drugs alter exposure.
Monitoring
Veterinarian should review liver status, clinical response and interacting drugs; oral tablets are contraindicated by their human label in chronic/active liver disease.
Client counseling
Report appetite loss, vomiting, jaundice or severe skin changes promptly. Review CYP2D6-related interactions and other antifungals.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow exact container storage instructions; secure topical preparations against licking or ingestion.
Brands, formulations & ingredient identity
Active ingredients
terbinafine hydrochloride
Other searchable names: terbinafine HCl
Lamisil tablets and Lamisil AT topical cream contain the same active moiety in different dosage forms. A topical cream is not an oral substitute.
The FDA tablet brand label cited is historical; current generic human tablets have their own labeling. Verify local availability rather than assuming the original brand is stocked.
Terbinafine hydrochloride describes the ingredient form. It is a different antifungal from fluconazole or itraconazole, despite overlapping clinical categories.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Lamisil
- Formulation
- Human oral tablets; historical FDA brand label
- Label / product scope
- Human product
Historical brand identity; check current product availability.
Product label / source ↗Lamisil AT
- Formulation
- Topical antifungal cream
- Label / product scope
- Human product
External-use product; not interchangeable with oral tablets.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.